Canaan and Polaris are two of nine firms on this years List to have closed on new funds this year, raising among them a total $3.935 billion. The firm invests in digital technologies across energy, infrastructure, and climate industries. Crunchbase Daily. The firm seeks to invest in the computer hardware, software, commercial services, and healthcare sectors. This article showcases our top picks for the best Oklahoma based Venture Capital companies. Largest investment: 34.2 million shares of Sana Biotechnology worth $856 million at the time of its IPO. WebAs of 2021, Venture capital-backed companies account for 62% of US public companies R&D spending! Mubadala is a sovereign wealth fund, investing on behalf of the United Arab Emirates and the government of Abu Dhabi. Largest investment: 37.5 million shares of Instil Bio worth $751 million at the time of its IPO, Total holding value of 2021 IPOs: $750.6 million. Always do your homework, check the VCs performance record, see whether you can tap into their network and expertise, and ensure the firm deals with companies in your stage. The firm seeks to invest in early-stage breakthrough technologies. Additionally, Bain Capital Crypto closed a $500 million fund in Flagship Pioneering offers a distinctive business strategy that conceives, develops, finances, and expands first-in-category ventures to revolutionize sustainability and human health. The firm is headquartered in San Francisco, California. August 02, 2021, 11:45am EDT Biotech companies, for their part, venture capital funds and government grants are also listed below and not included in the total. The business focuses on disruptive and clinically significant technologies with a long tradition of curative Biopharma investments and a recent focus on expanding digital health investments. For biotech in 2021 it paid to be private. Investment into biotech and health care boomed during the pandemic as thousands of venture capital firms turned their attention to breakthrough artificial intelligence, cancer-detection technology, mental health treatments, digital doctor visits, diagnostics and more. The report predicts venture capital (VC) activity and performance for next year. The overall investment in Biotech firms has grown significantly. WebThe 45 most important VCs in Texas, according to other VCs. The venture capital firm, Third Security, located in Radford, Virginia, is distinctive for its increasing global view and very patient approach. Early Stage VC, Later Stage VC, Merger/Acquisition, Founded in 2018, Ecliptic Capital is a venture capital firm based in Austin, Texas. Other firms focused on venture creation where they aggressively invest in a startup's founding and early years made the list with just a few investments. Urban Capital Network is a venture capital firm based in Houston, Texas. It seeks to invest in the information technology sector. Samantha Stokes , Stephanie Palazzolo , Madeline Renbarger , Darius Rafieyan, and Ben Bergman. The early-stage venture financing firm, Canaan Partners, focuses on game-changing innovations in information, digital technologies, and medical sciences. htmlbody height HTML body div The firm seeks to make investments in companies operating in business software, consumer internet, cloud service, enterprise software and other technology sectors. More than 90 companies have gone public, up from 81 in 2020 and 49 in 2019, according to SVB Leerink analysts. The firm seeks to invest in seed-stage, early-stage, and later-stage companies. Copyright 2021 by F50, Austin Texas | All Rights Reserved, 24 Most Active Venture Capital Firms in Texas 2021, https://www.chevron.com/technology/technology-ventures. Another six venture firms disclosed plans to raise new funds totaling an additional reported $2.78 billion; the actual number is undoubtedly higher, since one of those firms would not disclose a figure on its Form D. So who else joined those firms in investing capital in biotechs this year? Domain Associates has a large selection of Biopharma items in its portfolio, including cutting-edge genomics and RNA treatments. The teams diversity and integration offer in-depth expertise that produces tangible outcomes for its businesses and investors. Hundreds of investors financed these companies while they were privately held, and they held significant stakes when the companies went public. City (cities) where offices are located: Menlo Park, CA; Chevy Chase, MD; Timonium, MD; New York, Chicago; Cambridge, MA; as well as affiliate operations in Beijing; Shanghai; Bangalore; Mumbai. Largest investment: 16.2 million shares of Theseus Pharmaceuticals worth $259 million at the time of its IPO, Total holding value of 2021 IPOs: $988.4 million. , however, participated in Adagios Series A, B and C rounds. While health and biotech are often almost inextricably linked, its worth noting that of that investment, a significant portion is heading directly to companies that place themselves specifically in the biotechnology category. The firm specializes in investing in the early-stage firm. But two of those investment firms have emerged as major leaders, not only in the number of biotech funding rounds led, but also in overall dollars invested into the industry. WebThe organization aims to help startup companies commercialize new medical technologies by providing access to the vast resources of the worlds largest medical center. If investment continues at the current pace, 2022 could likely top 2020 for total funding. Over the next 12 months, the analysts expect to see more signs of overcrowding in the SPAC market, including a year on year decline in SPAC IPO volume. Versant, based in San Francisco, has $4.1 billion in assets under management and makes a handful of investments in new companies each year, typically investing $20 million to $30 million, a spokesperson said. The firm seeks to invest in B2B SaaS companies. 1 We also found that biotech Largest investment: 18.2 million shares of Adagio Therapeutics worth $46.9 million at the time of its IPO, Total holding value of 2021 IPOs: $468.7 million. CRO. See: http://www.sec.gov/Archives/edgar/data/1612343/000161234314000001/xslFormDX01/primary_doc.xml To learn more about these VC firms and their 2021 investments take a look at their Crunchbase profiles: Stay up to date with recent funding rounds, acquisitions, and more with the Bill Wood Ventures is a venture capital firm based in Austin, Texas. 6 On Nov. 6, the firm said it plans to move its Boston office in April 2015 to Cambridge, MA, after signing a lease for about 14,500 square feet in a new office building at 450 Kendall St. RA Capital led the companys $336 million Series C ahead of the companys August IPO, though the firm hadnt participated in the companys earlier funding rounds. The management team, combined with its advisory board, includes seasoned entrepreneurial, medical device sector, venture capital, regulatory, and scientific expertise. It is noteworthy that the company identifies various affiliate investment companies, or New River Management Funds, which are smaller corporate venture capital funds with a regional concentration. RA Capital, an investor based in Boston, raised an $880 million fund in October, all of which is set to go toward healthcare and life-science companies. Foresite, based in San Francisco, is a healthcare investor that does everything from incubating startups to acting as a crossover investor in companies about to go public. Leander, Texas 78641 Curative Ventures is a small VC based in Dallas that specializes in biotech investments. Founded in 2005, S3 Ventures is a venture capital firm based in Austin, Texas. The largest deal of 2021 was the transaction of Treeline Biosciences (USD 735m), while the most active investor was Alexandria Venture Investments with 51 investments in 2021. OrbiMed and. Business Products and Services (B2B), Consumer Products and Services (B2C), Software, Managing Directors Don Douglas, Michael Girdley, Mike Troy, and Cole Wollak. On the other hand, the number of special purpose acquisition companies (SPACs), which raise funds through an initial public offering (IPO) to acquire another company within two years, is expected to dwindle in 2021 compared to 2020, PitchBook said. 2021 was no different, as OrbiMed was involved in nine IPOs with aggregate holdings nearing $1 billion. Angermayer, who is also a movie producer, is especially interested in trying to develop psychedelics into medicines, with investments in ATAI Life Sciences and Compass Pathways, both of which focus on mental health. Founded in 2015, Next Coast Ventures is a venture capital firm based in Austin, Texas. Fierce Pharma. New startups with unique concepts are developing as the Global Biopharma and MedTech Industries experience unprecedented growth. WebExamples: 5AM Ventures, Atlas Venture, ARCH Venture Partners, Flagship, The Column Group, Versant, MPM Capital, Third Rock Ventures, Polaris Partners Tech-bio VCs: These are the software counterparts of the traditional biotech VCs -- the blue-chip venture funds that have decided to invest in biotech in addition to tech / software. The Indian startup/ VC ecosystem will truly come of age Since It has a variety of technologies spanning Biopharma, engineering, food, and other areas. Its biggest success, Moderna, has vaulted Flagship into biotech's top ranks with its COVID-19 vaccine. This venture capital firm is one of the top investors in the life sciences, with a track record of more than 260 firms and a total capital of $2.8 billion+. Latest biotech merger sees aimless Adamis snapped up by DMK - FierceBiotech 4h ago Shortlist a couple of venture capital firms that are likely to be interested in your company in terms of the products and the industry. MicroVentures is an online equity crowdfunding platform enabling angel investors to connect with startups to raise capital. The capital total is a staggering 46% increase from its last set of funds, closed in May 2021 at $1.3 billion. Founded in 2006, Breyer Capital is a venture capital firm headquartered in Menlo Park, California. 5 The firms Venrock Healthcare Capital Partners II fund submitted a Form D on March 11 stating that it planned to raise $200 million. The list is ordered starting with the companies who invested the most in biotechnology. (1), Current biopharma portfolio companies: Adamas, Balance Therapeutics, CardioDx, Crescendo Bioscience, DVS Sciences, Pacific Biosciences, Personalis, RainDance Technologies, Sequenta, City (cities) where offices are located: Seattle and Menlo Park, CA, Fund size and status: More than $2 billion under management across seven funds, Current fund: $377 million Frazier Healthcare VII, closed 2013, Current biopharma portfolio companies: Achaogen, Alcresta, Allena Pharmaceuticals, Amicus Therapeutics, Anaptys, Attercor, Cadence Pharmaceuticals, Chimerix, Cidara Therapeutics, Collegium Pharmaceutical, Portola Pharmaceuticals, QuatRx Pharmaceuticals, Rempex Pharmaceuticals, Semnur Pharmaceuticals, Silvergate Pharmaceuticals, Tobira Therapeutics, VentiRx Pharmaceuticals, #14 (tie). These VC firms led the most funding rounds for biotech startups this year between Jan. 1 and Dec. 1, according to Crunchbase data. Largest investment: 13.2 million shares of Lyell Immunopharma worth $225.8 million at the time of its IPO, Total holding value of 2021 IPOs: $400.2 million. The firm seeks to invest in companies operating in the information technology and tech-enabled services. Alta Partners. This fact is the cornerstone of the firms infrastructural drive in the biological sciences, healthcare, and Biotech company sectors. Cormorant Capital, a Boston-based investing group with $3 billion in assets under management, was founded in 2013 by Bihua Chen. Both of the companies DCVC held shares in that went public this year Recursion Pharmaceuticals and Zymergen were investments from DCVC's Deep Tech funds, a spokesperson said. Since launching its healthcare technology investments in 1993, the group has become one of the industrys top venture capitalists. Web2021 marked the second consecutive year of record private financing for biopharma with more than $28 billion raised, a 26% increase over 2020. The funds focus on the emerging science of individual health and through health the delivery of happiness. The analysis included 93 biotechs listed on the IPO trackers managed by BioPharma Dive and Endpoints News as of December 6. Arch, Novo Holdings, and Flagship Pioneering topped the list with more than $1 billion in equity. Venture capital in U.S. and Europe biotechnology industry 2015-2021 U.S. bioscience venture capital investments by segment 2018-2021 biotechnology funding by National Institutes for Health 2013-2023 WebThe 45 most important VCs in Texas, according to other VCs. Communications and Networking, Other Information Technology, Other IT Services, Systems and Information Management, Founding Partners Krishna Srinivasan and Venu Shamapant. Managing Directors Thomas Ball and Michael Smerklo. See: http://blogs.wsj.com/venturecapital/2014/04/04/refocused-mohr-davidow-ventures-is-raising-a-new-fund/ WebThe lifeblood of revolutionary medical technologies is venture funding. WebWith a total of USD 9.2bn, the oncology sector received the highest funding volume, followed by central nervous system (USD 6.0bn) and infectious diseases (USD 2.2bn). Largest investment: 26.6 million shares of Zymergen worth $825 million at the time of its IPO, Total holding value of 2021 IPOs: $1.1 billion. Amidst rising interest rates and the looming threat of recession, the once-hot IPO market has come to a grinding halt. Venture The firm seeks to invest in the computer Accel is a venture capital firm that concentrates on the following technology sectors: Consumer, Infrastructure, Media, Mobile, SaaS, Security, Customer care services, Enterprise software, and E-commerce. Founding Partners Carl Soderstrom and Clay Heighten, MD. However, as the COVID Biotechnology boom ends, it is becoming more challenging for entrepreneurs to get venture money. OrbiMed invests across the global healthcare sector, from early-stage venture capital to sizable publicly-listed enterprises. Webventure funding. The firm seeks to invest in the media, software, and healthcare sectors. Early Stage VC, Later Stage VC, Seed Round. Additionally, Bain Capital Crypto closed a $500 million fund in March 2022, and the firm announced a $2.4 billion Tech Opportunities fund earlier this month. Medtech. Here is a list of the most active most active bio-tech, pharma and life science investors. Media, Services (Non-Financial), Software, Accelerator/Incubator, Early Stage VC, Later Stage VC, Seed Round, President Gordon Daugherty, CEO Joshua Baer. They will explore which venture capital funds performed best during the pandemic, and of course be taking your questions live. Navigation show. WebAs of 2021, Venture capital-backed companies account for 62% of US public companies R&D spending! It has $3.7 billion in assets under management, a spokesperson said. Following is a list of the top 15 venture capital firms in 2023. Third-ranked Flagship Pioneering, for instance, was driven by just two IPOs in 2021. This information is up to date through 2009 - an incredibly difficult year for bio-tech companies to raise venture capital funding, as the financial crisis caused investing firms to become more cautious with their money, but many companies manage to attract VC investments in even in the toughest economic conditions. Sequoia Capital. The firm prefers to invest in the healthcare, manufacturing and pharmaceutical sectors. She has grown Cormorant into one of biotech top investors; the company was involved in 11 such IPOs in 2021. Fund size and status: More than $3 billion in committed capital across nine funds. Aziz Gilani, Sarah It closed its second Xontogeny-focused fund in May, giving it another $515 million to invest in a dozen or more companies. MedicoReach Domain Associates was one of the first investment firms to primarily focus its holdings in the Biosciences industry in 1985. Leading a funding round is a big undertaking. The Legal 500; Europe, Middle East & Africa . Fierce Healthcare. There is mixed news heading into 2021 on the COVID-19 pandemic front, with rising infection levels and a handful of vaccines showing promise. Commercial Products, Commercial Services, Computer Hardware, Pharmaceuticals and Biotechnology, Software. 12Figure calculated based on adding the value of the two current funds with the $3.5 billion previously disclosed by the firm. Octopus Ventures is a London and New York based venture capital firm, focused on backing unusually talented entrepreneurs. Over the last 31 years, the firm has managed a highly diversified $5 billion fund that comprises some of the top names in technology and life sciences. Polaris isnt alone. Our research shows that VC companies invested in 2,200 biotech start-ups worldwide in 2016; by 2021, that number had grown to 3,100. WebAs of 2021, Venture capital-backed companies account for 62% of US public companies R&D spending! , which conducts research and development of pharmaceuticals related to COVID-19. In 1999, Novo Nordisk and Novozymes partnered to form Novo Ventures (Nova A/S), a Danish private limited venture capital firm headquartered in Hellerup, Denmark. With $19 billion in assets under management, OrbiMed is set to be a leader next year as well. Fund size and status: More than $14 billion in committed capital across 14 funds, Current fund: $2.6 billion New Enterprise Associates 14 L.P., closed 2012, Current biopharma portfolio companies: 3-V Biosciences, Acadia Pharmaceuticals, Adaptimmune, Alimera Sciences, Amicus Therapeutics, Ardelyx, Blend Therapeutics, BrainCells, Cadence Pharmaceuticals, Cardioxyl Pharmaceuticals, Cerecor, Cleave Biosciences, Clovis Oncology, Cydan, Dermira, Edimer Pharmaceuticals, Envisia Therapeutics, Epizyme, Galera Therapeutics, Glycomimetics, Hydra Biosciences, Hyperion Therapeutics, Intarcia Therapeutics, Intrinsic Therapeutics, Liquidia Technologies, Loxo Oncology, Lumos Pharma, Mersana Therapeutics, Mirna Therapeutics, Nexchem, NexImmune, Novast Holdings, Predictive Biosciences, Prosensa, Proteostasis Therapeutics, Psyadon Pharmaceuticals, Ra Pharma, Rhythm Pharmaceuticals, Rigel Pharmaceuticals, Roka Bioscience, Satori Pharmaceuticals, Sunesis Pharmaceuticals, Supernus Pharmaceuticals, Targacept, Tesaro, Transcept Pharmaceuticals, Tracon Pharmaceuticals, Trevena, Zyngenia, 1 The firm was ending investments in life sciences, and raising a fund in the $200 million range, according to an April 4 news report in Venture Capital Dispatch, a blog of The Wall Street Journal, in which the firm declined comment. Nearly $20 billion in funding flowed into biotech companies developing cell-, gene- and tissue-based therapies last year, widely eclipsing the total invested in 2019 and ending up 50% higher than the previous record of $13.5 billion set in 2018. See here for a complete list of exchanges and delays. It features some jaw So far, the companies have raised a total of $12.2 billion in capital. Jan 6, 2023 12:43pm. Merger and acquisition, which many believed would revive the ecosystem, hasnt taken off yet. Fierce Biotech. Angel (individual), Early Stage VC, Later Stage VC, Seed Round, Managing Director of Fund I and II and Fund I Deal Committee Member Rob Tucci. 14On June 27, KPCB submitted Form D filings with the U.S. Securities and Exchange Commission disclosing plans to raise an early-stage growth fund of $450 million, known as KPCB XVI, as well as a later-stage fund of $750 million known as KPCB Digital Growth. Some VCs bet on a range of startups, like RA Capital, which had significant stakes in 18 companies that went public in 2021. In a handful of instances, figures and facts came from biographies of the firms principals available on the websites of investee companies and publicly available investor presentations posted online. These were the top 10 VC deals in Mass. This list includes corporate venture capital firms. Largest investment: 9.6 million shares of Erasca worth $153 million at the time of its IPO, Total holding value of 2021 IPOs: $539.4 million. Business Products and Services (B2B), Healthcare Technology Systems, Information Technology, Founder & Managing Partner Leonard Lenny Saizan Jr. The firm prefers to invest in seed-stage, early-stage, and later-stage companies. After all, you cannot rush your way into building long-term relationships! WebFounded in 1999, Chevron Technology Ventures is the corporate venture capital arm of Chevron and is based in Houston, Texas. Freelance Writers: How To Pitch Crunchbase News, Wiz Becomes $10B Cybersecurity Unicorn But Says New Money Wont Go To Israel Amid Turmoil Over Judicial Reform, Tech Jobs: Here Are Dozens Of Artificial Intelligence Startups Hiring Now. Samantha Stokes , Stephanie Palazzolo , Madeline Renbarger , Darius Rafieyan, and Ben Bergman. Alex Philippidis Senior News Editor Genetic Engineering & Biotechnology News. The investments we included were those disclosed in company S-1 filings, and the value of the holdings was based on the companies' initial pricing at the time of their IPOs. Texas Halo Fund is an investment firm based in Houston, Texas. 10 Figure calculated based on adding the value of the new $450 million fund with the $3.5 billion previously disclosed by the firm. The Indian startup/ VC ecosystem will truly come of age 2021 Update: Ranking biotech's top venture capital firms - STAT Our latest STAT Report is an update of the classic, this time with 2020 data. ranked first and second, respectively, on the two lists compiled using Crunchbase data. Founded in 2016, Blue Bear Capital is a venture capital firm based in Los Angeles, California. With the global venture capital investment market size reaching US$ 233.9 Billion in 2022, you might be wondering who the industry's biggest players are. Current fund: $265 million Atlas Venture IX, closed in 2013 (8), Current biopharma portfolio companies: Annovation Biopharma, Arteaus Therapeutics, Ataxion, Bicycle Therapeutics, CoStim Pharmaceuticals, Egalet, F-star, Harbour Antibodies, Horizon Pharma, InfaCare Pharmaceutical, Lysosomal Therapeutics, MiRagen Therapeutics, Mnemosyne Pharmaceuticals, Navitor Pharmaceuticals, Nimbus Discovery, Numerate, Padlock Therapeutics, RaNA Therapeutics, Rodin Therapeutics, Spero Therapeutics, Synlogic, Vitae Pharmaceuticals, Zafgen, City (cities) where offices are located: London, Geneva, San Francisco, and St. Helier, Jersey, Fund size and status: $3.8 billion in total committed capital across mixed and dedicated funds, of which about $1 billion is dedicated to life sciences, Current fund: 150 million ($200 million) Index Life Sciences Fund with co-investment by GlaxoSmithKline and Johnson & Johnson, closed 2012; 400 million ($550 million) Index Ventures VII, closed June 11, which the firm said will make seed and early-stage investments in tech startups. To date, over 70 of the companys life science products have received FDA approval. Vivo is based in Palo Alto, California, but also has offices in Beijing, Shanghai, Hong Kong, and Taiwan. Asia Pacific ; VC firms only invest in companies that have long-term growth potential of at least 10X their investment, and that already have considerable traction (very fast revenue This company specializes in life science and provides investments for start-ups and growing businesses. Technology and healthcare are two areas in which California-based New Enterprise Associates, Inc invests. WebJan 9, 2023 08:00am. See: https://www.sec.gov/Archives/edgar/data/1602264/000160226414000001/xslFormDX01/primary_doc.xml Karuna parts ways with executive as it gears up for schizophrenia drug's high-profile launch. Partners & Co-Founders Brad Bentz, Danielle Weiss Allen and Chris Shonk. Along with conventional medicinal biopharma, the firms portfolio also includes a variety of technologies and online health start-ups. Asia Pacific ; Asia Pacific ; Healthcare, Security Services (B2B), Social Content, Software, Buyout/LBO, Debt General, Early Stage VC, Later Stage VC, PE Growth/Expansion, Recapitalization, Seed Round. Khosla Ventures bears the interests of Vinods passion for mentoring founders and entrepreneurs. With the unprecedented growth in the global Biopharma and MedTech industries, new start-ups with novel ideas are emerging. California-based Interwest Partners focuses on healthcare and IT. The New York-based OrbiMed Healthcare Fund Management has made various investments in the life sciences sector, including MedTech and Biopharma. VC investment in the biopharma space is likely to surpass $20 billion in 2021, driven by the need to fund trials and build out research and development programs, as clinical trials resume and elective procedures restart. After peaking in 2021, venture funding to biotech startups slowed in 2022, with investment on pace to come in at least a third lower than last years levels. RA Capital led the companys $336 million Series C ahead of the companys August IPO, though the firm hadnt participated in the companys earlier funding rounds. This report is informational only. Based out of Dhahran (Saudi Arabia), the firm also operates through regional offices in North America and Europe. This data also illustrates the total number of biotech industry investment rounds each lead investor participated in during that time, including those rounds the firm led and those it let others lead. The Legal 500 > Europe, Middle East & Africa > France > Private equity: venture/growth capital. Polaris Partners became the latest VC firm in the money on November 24, when it announced it had closed on its $450 million seventh fund, to be focused on healthcare and technology investments. Research. Kleiner Perkins Caufield & Byers (KPCB), City (cities) where offices are located: Menlo Park, CA; San Francisco; Beijing; Shanghai, Fund size and status: More than $7 billion in assets under management across 19 funds (13), Current fund: $525 million KPCB XV, closed 2012 (13), Current biopharma portfolio companies:(14) ApniCure, Armo BioSciences, Atara Bio, Auxogyn, Crescendo Bioscience, Elcelyx, Epizyme, FivePrime Therapeutics, Focal, Foundation Medicine, Oculeve, Onyx Pharmaceuticals, Orexigen, Pacific Biosciences, Pharmacopeia, Pharmacyclics, Practice Fusion, Rapid Micro Biosystems, Tesaro, True North Therapeutics. Partners Jim Kim, Amit Mehta, Alex Kinniier, Jocelyn Doe, Mark H. Goldstein, and Mark Blackwell. Founded in 2014, Equinvest is comprised of entrepreneurs and senior managers.. . Essex Woodlands was established by the Essex Venture Fund. Founded in 2006, Silverton Partners is a venture capital firm and is based in Austin, Texas. 3. Although the two firms emerged as leaders in the data, they still make up a small part of the more than $120 billion in venture capital funds globally that poured into health and biotech startups as of Dec. 1 this year, Crunchbase data shows. WebThis list of companies in the venture capital space with more than $1m in revenue that have been acquired provides data on their funding history, investment activities, and acquisition trends. The entire Sprout healthcare technology team broke out into NLV in 2005. Biotech. This analysis didn't track how each VC managed their position after the IPO, such as buying or selling shares. The German pharma giant Bayer's VC arm has made high-profile investments in health companies, three of which went public in 2021: Century Therapeutics, Pyxis Oncology, and Recursion Pharmaceuticals. Essex Woodlands Health Ventures, City (cities) where offices are located: Palo Alto, CA; Houston; New York; London; Shanghai, Fund size and status: More than $2.5 billion under management across eight funds (4), Current fund: $900 million Fund VIII, closed 2009 (4), Current biopharma portfolio companies: Acura Pharmaceuticals, Biotoscana, Bioventus, Catalyst Biosciences, Chroma Therapeutics, Corium, Curis, Echo Therapeutics, Elusys Therapeutics, Horizon Pharma, IntegenX, LightSciences Oncology, Medicinova, Molecular Partners, Open Monoclonal Technology, Oraya Therapeutics, Revance Therapeutics, Symphogen, Ziopharm Oncology, City (cities) where offices are located: Cambridge, MA; New York; Palo Alto, CA, Fund size and status: $2.6 billion under management across seven funds, Current funds: $450 million Venrock VII, closed July 2014 and intended to invest in technology and healthcare companies; $350 million Venrock VI, closed 2010 (5), Current biopharma portfolio companies: Acceleron Pharma, Achaogen, Anacor Pharmaceuticals, Ariosa Diagnostics, Avalanche Biotech, AVEO Pharmaceuticals, Celladon, Cerulean, Constellation Pharmaceuticals, CymaBay Therapeutics, Fate Therapeutics, Hua Medicine, Infinity Pharmaceuticals, Intarcia Therapeutics, Ironwood Pharma, Juno Therapeutics, QuatRx Pharmaceuticals, Receptos, Vitae Pharmaceuticals, City (cities) where offices are located: Boston (6); South San Francisco, CA; Gainesville, FL; Munich, Fund size and status: More than $2.6 billion committed capital under management across five funds, Current fund: Approximately $300 million MPM BioVentures V L.P., closed 2010 (7), Current biopharma portfolio companies: 23andMe, Amphivena Therapeutics, Anthera Pharmaceuticals, Aratana Therapeutics, Astute Medical, Celladon, Cerecor, Chiasma, Conatus Pharmaceuticals, Epizyme, Iconic Therapeutics, Mitokyne, Proteon Therapeutics, Radius Health, Rhythm Pharmaceuticals, SAI, Selexys Pharmaceuticals, Sideris Pharmaceuticals, Solasia Pharma, Syndax Pharmaceuticals, Theraclone Sciences, True North Therapeutics, Vascular Pharmaceuticals, Verastem, City (cities) where offices are located: Princeton, NJ, and San Diego, Fund size and status: More than $2.7 billion under management across eight funds, Current fund: $500 million Domain Partners VIII, closed 2009, Current biopharma portfolio companies: Achaogen, Achillion Pharmaceuticals, Adynxx, Afferent Pharmaceuticals, Aldeyra Therapeutics, Alimera Sciences, Applied Proteomics, Ariosa Diagnostics, Ascenta Therapeutics, Asmacure, Astute Medical, Atara Biotherapeutics, aTyr Pharma, BioNano Genomics, Cantex Pharmaceuticals, Celator Pharmaceuticals, Clovis Oncology, CoDa Therapeutics, CoLucid Pharmaceuticals, Dicerna Pharmaceuticals, Domain Elite Holdings, Domain Russia Investments, Eddingpharm International Holdings, Epic Sciences, Esperion Therapeutics, Evoke Pharma, Five Prime Therapeutics, IntegenX, Marinus Pharmaceuticals, Meritage Pharma, NovaDigm Therapeutics, Ocera Therapeutics, Oraya Therapeutics, Orexigen Therapeutics, Otonomy, ProteinSimple, Regardo Biosciences, Sera Prognostics, Syndax Pharmaceuticals, Tobira Therapeutics, Tragara Pharmaceuticals, VentiRx Pharmaceuticals, Veracyte, Zogenix, Fund size and status: $2.8 billion under management across 10 funds, Current fund: $650 million InterWest Partners X, closed 2008, Current biopharma portfolio companies: Applied Genetic Technologies (AGTC), Alvine Pharmaceuticals, Arcion Therapeutics, Carbylan Therapeutics, Cebix, Centrexion, Cidara Therapeutics, Drais Pharmaceuticals, Eiger BioPharmaceuticals, Lycera, MacroGenics, Ocera Therapeutics, On Demand Therapeutics, Paratek Pharmaceuticals, PMV Pharma, QuatRx Pharmaceuticals, RadioRx, Tesaro, Trius Therapeutics, USDS, Xenon Pharmaceuticals, City (cities) where offices are located: Cambridge, MA.
